Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
J Antimicrob Chemother
; 77(4): 1166-1177, 2022 03 31.
Article
in En
| MEDLINE
| ID: mdl-35022730
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pneumonia, Bacterial
/
Anti-Bacterial Agents
Type of study:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
J Antimicrob Chemother
Year:
2022
Document type:
Article
Affiliation country:
Ireland